Introduction {#s1}
============

Based on the presence or absence of anticyclic citrullinated peptide (anti-CCP) antibodies, rheumatoid arthritis (RA) can be classified into anti-CCP positive and anti-CCP negative RA. Anti-CCP antibodies have been widely shown to be strong predictors of disease severity and radiological damage.[@R1] [@R2] It is currently a matter of some debate as to whether anti-CCP positive and anti-CCP negative RA are two distinct entities or represent two different subsets of one and the same disease.[@R3]--[@R5] Linkage and association analysis revealed the shared epitope (SE) to be associated only with anti-CCP positive RA and not with anti-CCP negative RA.[@R6] A study in twin pairs has shown that the estimated heritability of anti-CCP negative RA is 66% (95% CI 21% to 82%), similar to the heritability of anti-CCP positive RA, estimated at 68% (95% CI 55% to 79%).[@R7] In the same study, the SE was found to explain 18% of the genetic component of RA susceptibility in anti-CCP positive RA but only 2.4% in anti-CCP negative RA.

Several studies have investigated putative associations between different human leucocyte antigen (HLA) alleles or single nucleotide polymorphisms (SNPs) within the HLA region and predisposition to anti-CCP negative RA,[@R5] [@R6] [@R8]--[@R11] with contradictory results. A large meta-analysis, across four European populations, found only a weakly significant association between several HLA alleles and anti-CCP negative RA, but observed marked geographical differences.[@R12] Lack of consistency between studies might therefore be explained by a different sample size and power, by geographical differences in allele frequencies and association patterns or by different study designs or definitions of HLA genotypes (two vs four-digit typing, different classifications for the SE). A large study, performed on Caucasians of Northern European descent, investigated several HLA-DRB1 susceptibility and protective models and SE subgroups for association with RA after stratification by autoantibody status. Significant associations between several HLA-DRB1 alleles and anti-CCP negative RA were found.[@R13] Together, these findings strengthen the hypothesis that genetic factors predisposing to anti-CCP positive RA are different to those predisposing to anti-CCP negative RA.

A recent large meta-analysis brought the number of confirmed non-HLA RA susceptibility loci to 31.[@R14] However, most studies on the identification of RA susceptibility loci published to date have been performed in largely anti-CCP positive RA cohorts, thereby biasing the search of RA susceptibility loci towards genetic variants predisposing to anti-CCP positive RA. Importantly, most studies have been underpowered to identify anti-CCP negative RA predictors.

Very few studies have systematically compared the genetic basis of anti-citrullinated protein autoantibody (ACPA)-positive to ACPA-negative RA outside the HLA region. In a genome-wide association study (GWAS) recently performed in 774 anti-CCP negative RA patients, 1147 anti-CCP positive RA patients and 1079 common controls,[@R15] no SNP achieved genome-wide significance in the comparison between anti-CCP negative RA and controls, while the *PTPN22* gene was associated with anti-CCP positive RA, together with hundreds of SNPs located within the HLA locus on chromosome 6.

Candidate gene association studies and a subsequent meta-analysis have confirmed an association of *STAT4* polymorphisms with anti-CCP positive and negative RA.[@R16] [@R17] *IRF5* polymorphisms have been shown in independent studies to be more strongly associated with anti-CCP negative RA than with anti-CCP positive RA in Caucasians,[@R18] [@R19] while this differential association is controversial in Asians.[@R20] [@R21] No other SNPs have been convincingly associated with anti-CCP negative RA. Interestingly, the association of *PTPN22* polymorphisms with anti-CCP negative RA is controversial, with some investigators reporting association in anti-CCP negative patients.[@R22] [@R23] For example, a recent study investigating the usefulness of data derived from electronic health records tested multiple non-HLA RA susceptibility markers in 871 anti-CCP positive RA patients, 378 anti-CCP negative RA patients and 1212 common healthy controls.[@R24] Only *PTPN22* showed an association with anti-CCP negative RA with a p value\<0.05. Due to the small sample size of the anti-CCP negative subgroup, conclusions could be made only for SNPs in aggregate rather than for individual SNPs. The authors conclude that there is a partial overlap between the genetic basis of anti-CCP positive and anti-CCP negative RA.

We hypothesised that currently known RA susceptibility SNPs would show a differential association pattern in anti-CCP negative RA compared with anti-CCP positive RA. Therefore, we tested the 31 RA confirmed susceptibility loci for association with RA in a dataset comprising between 1935 and 3827 anti-CCP positive RA patients, between 808 and 1918 anti-CCP negative RA patients and between 11468 and 12392 healthy controls per genetic marker, the largest number of anti-CCP negative patients studied so far in this setting.

Methods {#s2}
=======

Data collection, SNP selection and genotyping {#s3}
---------------------------------------------

Confirmed RA susceptibility SNPs were selected from the large meta-analysis by Stahl *et al*.[@R14] Most of the SNPs had been already genotyped in RA cases and controls as part of several other projects conducted at our laboratory. Cohorts and patient characteristics are presented in the online supplementary table S1; genotyping and quality control procedures have been described elsewhere.[@R22] [@R25]--[@R27] All patients and controls were Caucasians originating from the UK satisfying the 1987 American College of Rheumatology classification criteria for RA. Only RA cases with an available anti-CCP status, as determined with the second generation CCP (CCP2) assay, were included in the analysis. Several studies/cohorts did not contain any controls. Therefore, anti-CCP positive RA cases or anti-CCP negative RA cases from different studies were pooled together and compared with controls. If a SNP reported in the study of Stahl was not available in a cohort, a SNP proxy was selected to fulfil the following requirements: linkage disequilibrium (r2) ≥0.90 with the original SNP and a maximum of three different SNPs for one specific locus across all datasets. If these requirements could not be fulfilled for one dataset, it was excluded from the analysis for that particular locus. Therefore, different numbers of cases and controls were available for analysis for different loci. The following HLA-DRB1 genotypes were considered as SE alleles: '0101' '0102' '0104' '0105' '0107' '0108' '0110' '0111' '0401' '0404' '0405' '0408' '0409' '0410' '0413' '0416' '0419' '0421' '0423' '0426' '0428' '0429' '0430' '0433' '0434' '0435' '0438' '0440' '0442' '0443' '0445' '1001' '1113' '1126' '1134' '1402' '1409' '1413' '1417' '1419' '1420' '1421' '1429' '1430' '1431' '1432' '1434' '1441' '1446' '1447' '1448'.

Statistical analysis {#s4}
--------------------

Multinomial logistic regression was applied to compute OR, 95% CI and p values for association between the minor allele at every locus and either anti-CCP-positive (OR~ccp-positive~) or anti-CCP-negative RA (OR~ccp-negative~), assuming additivity on the log-odds scale (ie, every locus was coded as 0,1 or 2 corresponding to the copy number of the minor allele). The minor allele was defined according to the allele frequency in the total population, including cases and controls. To test for differences between OR~ccp-positive~ and OR~ccp-negative~, the linear combination β+ -- β-, where β+ is log(OR~ccp-positive~) and β- is log(OR~ccp-negative~) was calculated, along with its standard error. This enables a p value for the difference in association to be calculated.

Due to a high pretest probability for association in anti-CCP positive RA, p values were not corrected for multiple testing in this subset. Based on previously published data, 32 of the 35 non-HLA SNPs tested have been confirmed to represent independent effects. Therefore, without assuming any prior probability for association in the anti-CCP negative RA subset, which is a stringent assumption, the Bonferroni-corrected significance threshold would be 1.6E-03. Statistical analysis was performed with Stata V.10.1 (Stata Statistical Software: Release 10; Stata Corp., College Station, Texas, USA).

Results {#s5}
=======

Thirty-one confirmed RA susceptibility loci,[@R14] some of which contain independent effects, were considered for analysis. Together, this represents a total of 36 markers, plus the SE. Actual SNPs and proxys are presented for each locus in [table 1](#T1){ref-type="table"}. The combination of datasets available led to a total number of 4068 anti-CCP-positive, 2040 anti-CCP-negative RA and 13009 healthy UK controls. The actual number of cases and controls varies for every locus from 1935 to 3827 for anti-CCP positive RA, from 808 to 1918 for anti-CCP negative RA and from 11468 to 12392 for healthy controls. Basic cohort characteristics are presented in the online supplementary table S1. The results of the association analysis are presented in [table 2](#T2){ref-type="table"}. As expected, every locus showed an association with anti-CCP positive RA with a p value\<0.05. The SE and the corresponding tag SNP were highly associated with anti-CCP positive RA with an OR of 4.08 and 2.68, respectively. Three other markers at *AFF3*, *CD28*, *PTPN22* and two at the *TNFAIP3* locus reached genome-wide significance (\<5E-08) in anti-CCP positive RA with OR of 1.17, 1.18, 1.91, 1.29 and 1.45, respectively. By contrast, only six non-HLA loci in total reach a p value below 0.05 in anti-CCP negative RA: *TNFAIP3, GIN1/C5orf30, STAT4, ANKRD55/IL6ST, BLK* and *PTPN22*. The three last loci remained significant at the Bonferroni corrected threshold of 1.6E-03. The SE, and its tag SNP, show an association with anti-CCP negative RA with an OR of 1.28 and 1.15, respectively. The online supplementary table S2 shows association results stratified by rheumatoid factor and anti-CCP positivity. The probability of obtaining, by chance, at least 7/36 associated loci at a significance level of 0.05 is 1.8E-03. Therefore, under a prior hypothesis of no association, there is still a significant accumulation of RA susceptibility loci associated with anti-CCP negative RA.

###### 

Single nucleotide polymorphism (SNP) markers and their proxys for the independent rheumatoid arthritis susceptibility loci considered for analysis. The shared epitope is not defined by SNP markers, but by a list of 4-digit HLA-DRB1 alleles described in the methods section

    Chromosome Locus name          Single nucleotide polymorphism markers                
  ------------ ------------------- ---------------------------------------- ------------ -----------
             1 CD2/CD58            rs11586238                                            
             1 FCGR2A              rs12746613                               rs10494360   
             1 MMEL1/TNFRSF14      rs10910099                               rs3890745    
             1 PTPN22              rs2476601                                rs6679677    
             1 PTPRC               rs10919563                               rs1932435    
             2 AFF3 locus 1        rs1160542                                rs11676922   rs9653442
             2 AFF3 locus 2        rs10865035                                            
             2 CD28                rs1980422                                             
             2 CTLA4               rs3087243                                rs231804     
             2 REL                 rs13031237                                            
             2 SPRED2              rs934734                                 rs17534670   
             2 STAT4               rs7574865                                             
             3 DNASE1L3/PXK        rs13315591                               rs9813011    
             4 IL2/IL21            rs6822844                                rs13151961   
             4 RBPJ                rs874040                                 rs10517086   
             5 ANKRD55/IL6ST       rs6859219                                             
             5 GIN1/C5orf30        rs26232                                  rs35797      
             6 CCR6                rs3093023                                rs6907666    rs3093024
             6 HLA-DRB1 0401 tag   rs6910071                                             
             6 PRDM1               rs548234                                              
             6 TAGAP               rs394581                                 rs169858     
             6 TNFAIP3 locus 1     rs6920220                                rs2327832    
             6 TNFAIP3 locus 2     rs13207033                               rs10499194   
             6 TNFAIP3 locus 3     rs5029937                                rs5029939    
             7 IRF5                rs10488631                               rs12531711   
             8 BLK                 rs2736340                                             
             9 CCL21 locus 1       rs951005                                              
             9 CCL21 locus 2       rs2812378                                rs10814138   
             9 TRAF1/C5            rs3761847                                             
            10 IL2RA locus 1       rs706778                                 rs10795791   rs7072793
            10 IL2RA locus 2       rs2104286                                             
            10 PRKCQ               rs4750316                                rs10796045   
            11 RAG1/TRAF6          rs540386                                 rs5030437    rs1046864
            12 KIF5A/PIP4K2C       rs1678542                                rs11172254   
            20 CD40                rs4810485                                rs1569723    
            22 IL2RB               rs3218253                                rs3218258    

###### 

OR with 95% CI and p value for association of the minor allele at every locus with anticyclic citrullinated peptide (anti-CCP) positive or anti-CCP negative rheumatoid arthritis (RA). The minor allele is defined according to the frequency in the total population, including cases and controls.

                           UK anti-CCP positive RA   UK anti-CCP negative RA   Comparison                                                                         
  ---- ------------------- ------------------------- ------------------------- ------------ ------ ------- ------ -------------- ---------- ------ ------- ------ ----------
  1    CD2/CD58            1.11                      1.05 to 1.18              3.68E-04     3827     11468 1.05   0.97 to 1.13   0.242        1918   11468 1.06   0.183
  1    FCGR2A              1.16                      1.07 to 1.25              2.28E-04     3467     11468 1.08   0.96 to 1.20   0.195        1563   11468 1.08   0.241
  1    MMEL1/TNFRSF14      0.88                      0.83 to 0.93              2.12E-05     3485     12394 0.97   0.89 to 1.05   0.426        1574   12394 0.91   0.045
  1    PTPN22              1.91                      1.77 to 2.05              3.91E-65     3813     12398 1.20   1.07 to 1.33   1.34E-03     1894   12398 1.60   7.11E-15
  1    PTPRC               0.91                      0.84 to 0.99              0.022        3600     11427 0.96   0.86 to 1.08   0.504        1580   11427 0.94   0.384
  2    AFF3 locus 1        1.17                      1.11 to 1.23              5.36E-09     3777     11832 1.05   0.98 to 1.13   0.165        1881   11832 1.11   0.008
  2    AFF3 locus 2        1.17                      1.09 to 1.25              2.64E-06     2378      8425 1.06   0.97 to 1.17   0.187         991    8425 1.10   0.086
  2    CD28                1.18                      1.12 to 1.26              3.15E-08     3826     11469 1.08   1.00 to 1.17   0.055        1912   11469 1.09   0.049
  2    CTLA4               0.91                      0.87 to 0.96              9.32E-04     3626     11975 0.94   0.88 to 1.02   0.121        1592   11975 0.97   0.475
  2    REL                 1.13                      1.07 to 1.20              1.58E-05     3196     10878 1.02   0.95 to 1.11   0.554        1437   10878 1.11   0.028
  2    SPRED2              0.91                      0.86 to 0.97              3.69E-03     2706      9032 0.97   0.89 to 1.06   0.565        1132    9032 0.94   0.198
  2    STAT4               1.13                      1.06 to 1.21              1.34E-04     3401     11822 1.11   1.02 to 1.20   0.015        1824   11822 1.02   0.656
  3    DNASE1L3/PXK        1.13                      1.02 to 1.24              0.014        3445     11486 0.93   0.80 to 1.08   0.338        1432   11486 1.21   0.020
  4    IL2/IL21            0.88                      0.82 to 0.95              1.03E-03     3402     11767 0.95   0.86 to 1.04   0.264        1814   11767 0.93   0.211
  4    RBPJ                1.14                      1.07 to 1.21              1.98E-05     3195     10879 1.02   0.94 to 1.11   0.681        1434   10879 1.12   0.021
  5    ANKRD55/IL6ST       0.85                      0.78 to 0.92              9.62E-05     2377      8428 0.80   0.70 to 0.90   2.42E-04      991    8428 1.07   0.357
  5    GIN1/C5orf30        0.88                      0.83 to 0.94              4.86E-05     3372     11260 0.88   0.80 to 0.95   2.32E-03     1410   11260 1.01   0.835
  6    CCR6                1.13                      1.07 to 1.19              1.48E-05     3423     11313 0.99   0.92 to 1.07   0.851        1508   11313 1.14   0.004
  6    HLA-DRB1 0401 tag   2.68                      2.50 to 2.88              9.97E-169    2378      8428 1.15   1.03 to 1.28   9.55E-03      991    8428 2.33   6.30E-47
  6    HLA-DRB1 SE         4.08                      3.64 to 4.56              1.18E-131    2366      1352 1.28   1.14 to 1.45   5.18E-05     1315    1352 3.18   2.56E-97
  6    PRDM1               1.06                      1.00 to 1.12              0.041        3827     11469 1.04   0.97 to 1.12   0.275        1916   11469 1.02   0.692
  6    TAGAP               0.90                      0.85 to 0.95              1.57E-04     3824     11466 0.97   0.90 to 1.04   0.416        1914   11466 0.92   0.068
  6    TNFAIP3 locus 1     1.29                      1.21 to 1.37              3.70E-16     3659     12392 1.09   1.00 to 1.18   0.048        1862   12392 1.18   3.52E-04
  6    TNFAIP3 locus 2     0.89                      0.84 to 0.95              2.72E-04     3425     11923 0.93   0.85 to 1.02   0.109        1497   11923 0.96   0.383
  6    TNFAIP3 locus 3     1.45                      1.28 to 1.65              1.33E-08     3414     12021 0.91   0.73 to 1.13   0.374        1460   12021 1.60   7.36E-05
  7    IRF5                1.12                      1.02 to 1.23              0.016        2739      9043 1.09   0.95 to 1.24   0.213        1175    9043 1.03   0.696
  8    BLK                 1.09                      1.03 to 1.16              3.77E-03     3490     11481 1.15   1.05 to 1.25   1.53E-03     1525   11481 0.95   0.332
  9    CCL21 locus 1       0.92                      0.85 to 1.00              0.048        3199     10878 1.01   0.91 to 1.13   0.833        1439   10878 0.91   0.145
  9    CCL21 locus 2       1.13                      1.07 to 1.20              7.68E-06     3642     11936 1.04   0.97 to 1.12   0.274        1855   11936 1.09   0.046
  9    TRAF1/C5            1.10                      1.04 to 1.16              7.54E-04     3135     11544 1.02   0.94 to 1.10   0.698        1447   11544 1.08   0.073
  10   IL2RA locus 1       1.14                      1.06 to 1.23              3.21E-04     1935      5477 1.07   0.96 to 1.19   0.224         808    5477 1.07   0.240
  10   IL2RA locus 2       0.88                      0.83 to 0.93              2.71E-05     3806     12396 0.97   0.90 to 1.05   0.450        1896   12396 0.91   0.033
  10   PRKCQ               0.87                      0.82 to 0.94              1.18E-04     3657     12427 0.95   0.86 to 1.04   0.281        1624   12427 0.92   0.132
  11   RAG1/TRAF6          0.92                      0.85 to 0.99              0.032        3440     11379 0.98   0.88 to 1.09   0.723        1556   11379 0.94   0.285
  12   KIF5A/PIP4K2C       0.90                      0.85 to 0.95              1.81E-04     3688     12452 0.95   0.88 to 1.02   0.135        1881   12452 0.95   0.237
  20   CD40                0.89                      0.84 to 0.95              4.36E-04     3640     11971 1.02   0.94 to 1.11   0.594        1858   11971 0.87   0.005
  22   IL2RB               1.15                      1.08 to 1.21              3.15E-06     3811     12392 1.08   1.00 to 1.16   0.057        1900   12392 1.06   0.164

N cases, cont: number of cases or controls with available genotype. Comparison ORpos/ORneg: effect size ratio between the OR in CCP-positive and CCP-negative RA, with the p value for its significance. The CI of the effect size OR is not shown to avoid overloading the table

Due to the different number of cases in anti-CCP positive and negative RA, simply comparing p values would be misleading. Therefore, the significance of the observed difference in association between anti-CCP positive and negative RA was addressed by computing a comparison OR (or effect size OR) and its corresponding p value (column 'comparison' in [table 2](#T2){ref-type="table"}). This allows the classification of the loci into three distinct categories ([table 3](#T3){ref-type="table"} and [figure 1](#F1){ref-type="fig"}): the *HLA-DRB1 SE, PTPN22* and one marker at TNFAIP3 are associated with anti-CCP positive and negative RA, but show a clear differential association with an effect size significantly higher in anti-CCP positive RA (category 1). Other loci, like *C5orf30* or *STAT4* are associated with RA irrespective of the serological status, with the effect size not differing significantly between subsets (category 2: anti-CCP independent associations). A third category comprises anti-CCP positive specific loci with no significant association detected in anti-CCP negative RA; however, the p value for the effect size ratio is below 0.05. The remaining loci could not be classified into one of these three categories, because although they are associated with anti-CCP positive RA with a p value\<0.05, the effect in anti-CCP-negative RA is not significantly different from that in anti-CCP-positive RA, nor significantly different from the null. This last situation can only be explained by a lack of power. Indeed, for the vast majority of markers in category 3, the study has, in the anti-CCP negative subgroup, a power between 60% and 90% at the 0.05 significance level to detect an association of the same effect size as observed in the anti-CCP positive subgroup, while power drops to between 15% and 50% for most of the unclassifiable markers. As an example in category 3, an association of an effect size of 1.17 would be detected for *AFF3 locus 1* with a power of 89.3% at the 0.05 significance level for a minor allele frequency (MAF) of 45.5% in controls. An association of a larger effect size of 1.45 would be detected for the intronic *TNFAIP3* marker with a power of 81.6% at the 0.05 significance level for a MAF of 3.5% in controls. The detection power drops for smaller effects around 1.13, but is still 64.4% *CCL21* locus 2 (MAF in controls 34.2%). However, although *CD2/CD58* has been genotyped in 1918 anti-CCP negative cases, it is not possible to classify it as being associated with anti-CCP positive, negative or both because the power to detect an effect of 1.11 in anti-CCP negative with a MAF of 24% in controls is only 46.1%.

![OR and 95% CI for different single nucleotide polymorphism association patterns. **PTPN22**: significant association in both serotypes, significantly different. **C5orf30**: significant association in both serotypes with the same effect size. **CCR6**: only associated in anticyclic citrullinated peptide (anti-CCP) positive rheumatoid arthritis (RA). **BLK**: associated in both serotypes, effect size slightly, but not significantly, larger in anti-CCP negative RA. **TNFAIP3** locus 3: only associated in anti-CCP positive RA, highly significant difference. *PTPN22*, *C5orf30*, *CCR6* are prototypic examples illustrating the three categories presented in [table 3](#T3){ref-type="table"}.](annrheumdis-2011-201225f01){#F1}

###### 

Schematic classification of RA susceptibility loci into three categories depending on their association pattern in anti-CCP positive and negative RA

  Category           Associations                                                                               Locus Name
  ------------------ ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------
  1                  Both CCP positive and negative RA, stronger in CCP positive RA                             HLA-DRB1 SE, PTPN22, TNFAIP3 locus 1
  2                  Both CCP positive and negative RA, equally strong in both                                  ANKRD55, BLK, C5orf30, STAT4
  3                  CCP positive RA only, significant difference between CCP positive and negative RA          AFF3 locus 1, CCR6, CCL21 locus 2, IL2RA locus 2, CD28, CD40, PXK, REL, RBPJ, TNFRSF14, TNFAIP3 locus 3
  Not classifiable   CCP positive RA only, but no significant difference between CCP positive and negative RA   All others

CCP, cyclic citrullinated peptide; RA, rheumatoid arthritis.

Of note, is the fact, that the effect size of all but two loci, *ANKRD55* and *BLK* ([figure 1](#F1){ref-type="fig"}), is larger in anti-CCP positive RA than in anti-CCP negative RA. However, due to relatively wide CIs, the effect size ratio is not significant, so these two loci are both classified in category 2.

Interestingly, the three known independent effects at *TNFAIP3* are classified in at least two different categories ([table 3](#T3){ref-type="table"}). At this locus, the most profound discordance between anti-CCP positive and negative RA is seen for the intronic marker ([figure 1](#F1){ref-type="fig"}), which displays a genome-wide significant association of a 'large' effect size in anti-CCP positive RA with an OR above one (OR 1.45, 95% CI 1.28 to 1.65, p=1.33×10^−8^), representing a risk factor for this disease. However, no significant association is detected in anti-CCP negative RA (OR 0.91, 95% CI 0.73 to 1.13, p=0.37). The effect size ratio is highly significant (OR 1.60, 95% CI 1.27 to 2.02, p=7.36×10^−5^).

Discussion {#s6}
==========

With a number of anti-CCP-negative RA patients ranging from 808 to 1918 per locus, our study represents the largest genetic study on anti-CCP negative RA to date. The 31 confirmed RA susceptibility loci identified so far have been primarily established in anti-CCP positive RA, and the meta-analysis by Stahl *et al*[@R14] included only seropositive RA. The effect size and strength of association of the loci identified in the meta-analysis by Stahl *et al* and in the anti-CCP positive RA subset of this study are very consistent. Slight differences might be related to the difference of power for certain loci and to the use, in some instances, of several different proxies for one locus. It should be noted that we defined the minor allele frequency according to the frequency in the total population, including cases and controls. Since the minor allele frequency is close to 50% for *SPRED2* in the meta-analysis by Stahl, where the minor allele frequency is based on controls only, the G allele is the minor allele, while it is the major allele in this study. This results in an inversion of the OR for association with anti-CCP positive RA. All loci tested here are associated with anti-CCP positive RA with p\<0.05, and five loci reach genome-wide significance (\<5E-08).

Interestingly, we show a strong and highly significant association of the SE with anti-CCP negative RA; the association remains present after stratification for rheumatoid factor (online supplementary table S2), which is consistent with the findings of a large study performed in patients from the same genetic background.[@R13] However, several smaller studies, performed in populations of different origins, did not detect significant association, likely due to a lack of power or ethnic differences. A large European meta-analysis, taking only 2-digit typing into account across several different European populations, concluded that there were weak, but no robust associations between any HLA-DRB1 alleles and anti-CCP negative RA.[@R12] The number of anti-CCP negative RA patients tested in our study is much higher than that in the meta-analysis or any other study, and confirms that the SE is associated with anti-CCP negative RA in UK Caucasians.

Compared with the results in anti-CCP positive RA, where all loci show evidence for association, only seven loci achieve a p value below 0.05 in the anti-CCP negative subgroup. However, this number is higher than reported to date, and represents a statistically significant overlap (p=0.0018). Among the loci tested here, 32 non-HLA loci have been convincingly shown to be independently associated in anti-CCP positive RA. Therefore, without assuming any prior probability for association, the Bonferroni-corrected significance threshold would be 1.6E-03. Three non-HLA loci would remain significantly associated with anti-CCP negative RA after the Bonferroni correction: *ANKRD55/IL6ST, BLK* and *PTPN22*.

Interestingly, both *BLK* and *STAT4* are confirmed systemic lupus erythematosus (SLE) susceptibility loci and it would be interesting to investigate the overlap of other SLE loci with anti-CCP negative disease. Our findings confirm those of the previous reports showing association in both anti-CCP positive and negative RA subgroups at the *STAT4* locus. *IRF5*, which has been found to be associated with anti-CCP negative RA by previous investigators, is not associated with anti-CCP negative RA in this study. However, it should be noted that the current study only had 19.6% power to detect an association of an effect size of 1.12 at the 0.05 significance level. In addition, a differential association of this marker with RA and its different serotypes in different ethnic groups, or gene-environment interactions, might further account for the lack of association seen here in anti-CCP negative patients.

The effect size of *BLK* and *ANKRD55/IL6ST* is larger in anti-CCP negative RA than in anti-CCP positive RA, although this difference does not reach statistical significance. All other loci show a higher effect size in anti-CCP positive RA. This can be explained by the fact that loci tested here have been primarily identified in cohorts containing mainly or exclusively anti-CCP positive patients.

The genetic difference between the two RA serotypes can be particularly illustrated by the association pattern of the intronic locus at *TNFAIP3*: it is strongly associated with anti-CCP positive RA, but not with anti-CCP negative RA, despite a detection power of over 80%; the difference in OR is statistically significant. The intronic locus at *TNFAIP3* therefore represents a risk factor for anti-CCP positive RA, but not for anti-CCP negative RA in this analysis.

The present study shows a genetic contrast between anti-CCP positive and anti-CCP negative RA and allows the classification of known RA susceptibility SNPs in different categories. The first category comprises markers associated with both subsets, but their effect size is significantly larger in anti-CCP positive RA. Although anti-CCP negative RA could not be clearly divided into distinct clinical subphenotypes in a recent study in the Netherlands,[@R28] it might still comprise several genetically and serologically different subsets, based for example on the presence of ACPA, other than anti-CCP antibodies.[@R29] The second category contains SNPs, similarly associated in both anti-CCP positive and negative RA, with the same effect size. The third category comprises SNPs associated with anti-CCP positive RA, but not with anti-CCP negative RA and the effect size ratio is statistically significant. A lack of association of some markers, while others are associated with disease irrespective of the serological status, suggests that RA susceptibility markers might cluster to different molecular pathways, some associated with autoantibody production, others not.

In summary, among 33 independent genetic loci tested in this study, 18 could be classified into three different categories, according to their association pattern, while 15 could not, mainly due to lack of power. Seven markers show an association with anti-CCP negative RA, while 11 others are unlikely to be associated. The use of a multinomial logistic regression analysis leading to three p values, as described here (anti-CCP positive RA, anti-CCP negative RA, effect size ratio), represents a straightforward method to classify markers into three meaningful categories or to exclude them from classification, if only one p value out of three is significant. This latter situation occurs mainly when the power is low. The accuracy of classification depends on the definition of the significance threshold. If a Bonferroni corrected p value is used for classification, markers with p values between 0.05 and 1.6E-03 would change category. Markers with highly significant associations and effect size ratio like PTPN22 can be considered as accurately categorised. Future studies might identify more categories; for example, for makers associated exclusively with anti-CCP negative RA, or displaying a larger effect size in anti-CCP negative RA than in anti-CCP positive RA.

Despite this being the largest sample of anti-CCP negative cases studied to date, the main limitation remains lack of power for many markers. This is particularly pertinent to the loci, which could not be classified into one of the three categories presented here. Larger sample sizes will be required to explore these loci more fully. Six thousand five hundred anti-CCP negative patients and 11 000 controls would be required to detect an effect size of 1.10 with a power of 80% for a marker present at a MAF of 28% in controls (average MAF of RA susceptibility loci in controls reported in the study by Stahl *et al*[@R14]).

The low number of anti-CCP positive RA susceptibility loci associated with anti-CCP negative RA highlights the need for a well-powered GWAS for the discovery of yet unknown anti-CCP negative RA specific loci. The current study presents genetic differences and similarities between anti-CCP positive and anti-CCP negative RA. Although the two disease serotypes show significant differences in disease course and severity, anti-CCP antibodies are currently not used to guide treatment decisions in clinical practice. However, the results presented here highlight the need for genetic analyses of susceptibility, severity and treatment response to consider the two serotypes both separately and together for future investigations.
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